Product Description: Doxapram-d8 is deuterated labeled Doxapram (HY-B0551). Doxapram inhibits TASK-1, TASK-3 and TASK-1/TASK-3 heterodimer channels with EC50s of 410 nM, 37 μM and 9 μM, respectively.
Applications: Neuroscience-Neuromodulation
Formula: C24H22D8N2O2
References: [1]Russak EM, et al. Impact of Deuterium Substitution on the Pharmacokinetics of Pharmaceuticals. Ann Pharmacother. 2019 Feb;53(2):211-216./[2]Peers, C., Effects of doxapram on ionic currents recorded in isolated type I cells of the neonatal rat carotid body. Brain Res, 1991. 568(1-2): p. 116-22./[3]Anderson-Beck, R., et al., Doxapram stimulates dopamine release from the intact rat carotid body in vitro. Neurosci Lett, 1995. 187(1): p. 25-8./[4]Cotten JF, et al. The ventilatory stimulant doxapram inhibits TASK tandem pore (K2P) potassium channel function but does not affect minimum alveolar anesthetic concentration. Anesth Analg, 2006, 102(3), 779-785.
Molecular Weight: 386.56
Research Area: Neurological Disease
Solubility: 10 mM in DMSO
Target: Isotope-Labeled Compounds;Potassium Channel
English
Deutsch
